Skip to main content

Table 4 Baseline cognitive assessment data

From: Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial

 

BI 2 mg QD 

(n = 123)

BI 5 mg QD 

(n = 122)

BI 10 mg QD 

(n = 122)

BI 25 mg QD 

(n = 123)

Placebo 

(n = 120)

Total 

(n = 610)

ADAS-Cog11total score

N

123

122

122

123

119

609

Mean (SD)

18.8 (7.9)

18.8 (7.4)

19.6 (7.8)

19.6 (7.3)

18.2 (8.0)

19.0 (7.7)

MMSE total score

N

123

122

122

123

119

609

Mean (SD)

21.3 (3.1)

21.4 (3.1)

21.6 (3.1)

21.5 (3.2)

21.4 (3.0)

21.4 (3.1)

  1. ADAS-Cog11 Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11, MMSE Mini-Mental State Exam, QD once daily, SD standard deviation